 |
市場調查報告書
商品編碼
1983270
結合疫苗市場：按產品類型、適應症、病原體類型、患者類型和地區分類Conjugate Vaccine Market, By Product Type, By Disease Indication, By Pathogen Type, By Patients Type, By Geography |
||||||
預計到2026年，結合疫苗市場規模將達到259.66億美元，到2033年將達到492.2億美元。預計從2026年到2033年，其複合年成長率將達到9.6%。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2025 | 市場規模（2026 年） | 259.66億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2026-2033 |
| 預測期（2026-2033 年）複合年成長率 | 9.60% | 預計金額（2033 年） | 492.2億美元 |
結合疫苗將弱抗原與強抗原結合，使免疫系統對弱抗原產生更強的反應，從而提供主動免疫。在結合疫苗中，弱抗原與強抗原共用結合，引發針對弱抗原的更強免疫反應。弱抗原是一種與強蛋白抗原結合的多醣體。
結合疫苗針對多種導致疫苗可預防死亡的主要原因疾病。結合疫苗的優點包括誘導免疫記憶和減少細菌無症狀攜帶，從而顯著提高群體免疫力。這些疫苗可提供針對不同細菌菌株的免疫力。例如，根據美國疾病管制與預防中心 (CDC) 2019 年 4 月的數據，截至 2022 年 1 月 24 日，肺炎鏈球菌結合疫苗（PCV13）可預防 13 種肺炎鏈球菌菌株感染。同時，美國食品藥物管理局(FDA) 於 2021 年核准了PCV15 和 PCV20 用於 18 歲及以上成人。臨床試驗數據顯示，PCV15 和 PCV20 與 PCV13 一樣，能夠刺激人體免疫系統產生抗體，幫助抵抗肺炎鏈球菌。
市場動態
在預測期內，肺炎病例的增加預計將推動全球結合疫苗市場的成長。例如，2021年8月，美國國家生物技術資訊中心（NCBI）發布了一份關於「社區獲得性肺炎」的報告，該報告估計全球社區獲得性肺炎的發生率為每千人年1.5至14例，並指出其發病率受地區、季節和人口統計特徵的影響。在美國，社區型肺炎的年發生率為每萬名成年人24.8例，且發病率隨年齡增加，但入住加護病房患者的死亡率高達23%。
預計各國政府加強推廣新疫苗將推動全球結合疫苗市場在預測期內成長。例如，2021年10月，印度衛生部長曼舒克·曼達維亞在「自由甘露節」（Azadi ka Amrit Mahotsav）期間，啟動了13價肺炎球菌結合疫苗（PCV）在全國範圍內的推廣接種，該疫苗是「全民免疫計畫」（UIP）的一部分。同時，印度也提供了有關PCV的公共關係宣傳和推廣資料。
本報告的主要特點
- 本報告指出了各個細分市場的潛在商機，並概述了該市場中一系列有吸引力的投資提案。
- 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本文根據以下參數，介紹了全球結合疫苗市場主要企業的概況：公司概況、產品系列、主要亮點、財務績效和策略。
- 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
- 《全球結合疫苗市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過分析全球結合疫苗市場中使用的各種策略矩陣來促進決策。
目錄
第1章：分析目標與假設
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 阻礙因素
- 市場機遇
- 影響分析
- 市場趨勢
- 主要進展
- 產品平臺分析
- 投資和政府舉措
- GAVI PATH計劃詳情
- 企業合併（M&A）
- 法規環境
- 波特五力分析
- PEST分析
第4章 全球結合疫苗市場：依產品類型分類（2026-2033 年）
- 概述
- 單價結合疫苗
- 多價結合疫苗
第5章：全球結合疫苗市場：依適應症分類（2026-2033 年）
- 概述
- 肺炎球菌
- 流感
- 腦膜炎奈瑟菌
- 傷寒
第6章 全球結合疫苗市場：依病原體類型分類（2026-2033 年）
- 概述
- 細菌
- 病毒性的
第7章 全球結合疫苗市場：依病患類型分類（2026-2033 年）
- 概述
- 兒童
- 成人
第8章 全球結合疫苗市場：按地區分類（2026-2033年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第9章 競爭情勢
- 熱圖分析
- 公司簡介
- Sanofi SA
- Pfizer, Inc.
- Merck &Co., Inc.
- GlaxoSmithKline plc.
- Bharat Biotech
- Serum institute of India Pvt. Ltd
- Biological E. Limited.
- Bio-Med
- Biological E Limited
- CSL Limited
- Novartis AG
- Vaxcyte
- GSBPL
- Taj Pharmaceuticals Limited.
- Bavarian Nordic
第10章
- 參考
- 分析方法
- 關於 Coherent Market Insights
Conjugate Vaccine Market is estimated to be valued at USD 25,966 Mn in 2026 and is expected to reach USD 49,220 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 25,966 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.60% | 2033 Value Projection: | USD 49,220 Mn |
Conjugate vaccine is a combination of a weak antigen with a strong antigen so as to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.
Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, on January 24, 2022 according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria. Whereas in 2021, US FDA (Food and Drug Administration) licensed PCV15 and PCV20 for use in adults 18 years or older. Clinical trial data showed that PCV15 and PCV20 caused the body's immune system to create antibodies, which helped fight the pneumococcal bacteria, similar to PCV13.
Market Dynamics
Increasing prevalence of pneumonia cases are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in August 2021, National Center for Biotechnology Information, published a report on Community-Acquired Pneumonia, which reported that the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the U.S., the annual incidence is 24.8 cases per 10,000 adults with higher rates as age increases, whereas the mortality rate is as high as 23% for patients admitted to the intensive care unit.
Increasing initiatives taken by the governments of countries to launch new vaccines are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in October 2021, Union Health Minister (India), Dr. Mansukh Mandaviya, launched a nationwide expansion of Pneumococcal 13-valent Conjugate Vaccine (PCV) under the Universal Immunization Programme (UIP) as a part of Azadi ka Amrit Mahotsav. Whereas, on the other hand communication and awareness packages on PVC were also made available in India.
Key features of the study
- This report provides an in-depth analysis of the global conjugate vaccine market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 - 2030), considering 2021, as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
- It profiles key players in the global conjugate vaccine market based on following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include, Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, Bio-Med, Bavarian Nordic, CSL Limited, Novartis AG, Vaxcyte, GSBPL, Taj Pharmaceuticals Limited, and Bavarian Nordic
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global conjugate vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global conjugate vaccine market
Market Segmentation
- Product Type Insights (Revenue, USD Mn, 2026 - 2033)
- Monovalent Conjugate Vaccine
- Multivalent Conjugate Vaccine
- Disease Indication Insights (Revenue, USD Mn, 2026 - 2033)
- Pneumococcal
- Influenza
- Meningococcal
- Typhoid
- Pathogen Type Insights (Revenue, USD Mn, 2026 - 2033)
- Bacterial
- Viral
- Patients Type Insights (Revenue, USD Mn, 2026 - 2033)
- Pediatric
- Adults
- Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Sanofi S.A
- Pfizer, Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Bharat Biotech
- Serum institute of India Pvt. Ltd.
- Biological E. Limited
- Bio-Med
- Bavarian Nordic
- CSL Limited
- Novartis AG
- Vaxcyte
- GSBPL
- Taj Pharmaceuticals Limited
- Bavarian Nordic
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Pathogen Type
- Market Snapshot, By Patient Types
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Pipeline Analysis
- Investments and Government Initiatives
- GAVI and PATH Program Details
- Merger and Acquisition
- Regulatory Scenario
- PORTER'S Five Forces
- PEST Analysis
4. Global Conjugate Vaccine Market, By Product Type, 2026-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Monovalent Conjugate Vaccine
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Multivalent Conjugate Vaccine
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global Conjugate Vaccine Market, By Disease Indication, 2026-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Pneumococcal
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Influenza
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Meningococcal
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Typhoid
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Conjugate Vaccine Market, By Pathogen Type, 2026-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Bacterial
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Viral
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
7. Global Conjugate Vaccine Market, By Patient Type,2026-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Paediatric
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Adult
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
8. Global Conjugate Vaccine Market, By Region, 2026-2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
- Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
- Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
- Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
- Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
- Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
- Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Heat Map Analysis
- Company Profile
- Sanofi S.A
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bharat Biotech
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Serum institute of India Pvt. Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Biological E. Limited.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bio-Med
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Biological E Limited
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- CSL Limited
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Vaxcyte
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GSBPL
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Taj Pharmaceuticals Limited.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bavarian Nordic
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
10. Section
- References
- Research Methodology
- About Us
